Articles from FUJIFILM Biosciences

FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media
FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue.
By FUJIFILM Biosciences · Via Business Wire · May 6, 2026
FUJIFILM Irvine Scientific Now Officially FUJIFILM Biosciences
FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced the Company has officially changed its legal name from FUJIFILM Irvine Scientific, Inc., to FUJIFILM Biosciences Inc., effective January 1, 2026. The FUJIFILM Biosciences’ name builds upon the Company’s roots as a pioneer in the cell culture media industry that through a core focus on people, innovation, and quality now serves a much broader life science community and customers.
By FUJIFILM Biosciences · Via Business Wire · January 5, 2026
FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium to Enable Gene Therapy Production
FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of gene therapies.
By FUJIFILM Biosciences · Via Business Wire · September 15, 2025
Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions
FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort. The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects Fujifilm’s commitment to Life Sciences, offering fully integrated, end-to-end solutions across the drug development lifecycle—from research and discovery to clinical and commercial manufacturing.
By FUJIFILM Biosciences · Via Business Wire · June 2, 2025